GI
KROS icon

GAMMA Investing’s Keros Therapeutics KROS Stock Holding History

GAMMA Investing’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.2K Buy
1,245
+421
+51% +$4.6K ﹤0.01% 3155
2026
Q2 		$8.82K Buy
824
+603
+273% +$6.72K ﹤0.01% 3275
2026
Q1 		$2.44K Sell
221
-93
-30% -$1.44K ﹤0.01% 3601
2025
Q4 		$6.39K Sell
314
-47
-13% -$825 ﹤0.01% 3172
2025
Q3 		$5.71K Sell
361
-13
-3% -$192 ﹤0.01% 3123
2025
Q2 		$4.99K Buy
374
+137
+58% +$1.85K ﹤0.01% 3117
2025
Q1 		$2.42K Buy
237
+206
+665% +$2.39K ﹤0.01% 3357
2024
Q4 		$491 Sell
31
-36
-54% -$1.87K ﹤0.01% 3574
2024
Q3 		$3.89K Buy
67
+23
+52% +$1.14K ﹤0.01% 2846
2024
Q2 		$2.01K Buy
44
+2
+5% +$107 ﹤0.01% 2880
2024
Q1 		$2.78K Buy
42
+5
+14% +$296 ﹤0.01% 2637
2023
Q4 		$2.05K Buy
+37
New +$1.16K ﹤0.01% 2572

Other funds holding KROS

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GAMMA Investing's KROS Position: Q3 2026 in Review

GAMMA Investing increased its Keros Therapeutics (KROS) stake by 51% in Q3 2026, buying an estimated $4.6K and bringing the position to 1,245 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3155.

GAMMA Investing first reported a position in KROS in Q4 2023 and has held it in 12 quarters since. 6 funds tracked by Wall St. Rank hold KROS as of Q3 2026.

  • GAMMA Investing held 1,245 shares of Keros Therapeutics worth $14.2K as of Q3 2026.
  • GAMMA Investing bought 421 Keros Therapeutics shares in Q3 2026, an estimated $4.6K.
  • Keros Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3155 holding.
  • GAMMA Investing first reported a position in Keros Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • 6 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.